← All trials
NCT04998344
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 7, 2021
- Primary completion
- Aug 14, 2022
- Completion date
- Dec 31, 2023
- First posted
- Aug 10, 2021
- Last posted
- Aug 10, 2021
- Enrollment
- 3800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BergenLead sponsor
- University of BergenOverall official - principal investigator
- Norwegian University of Science and TechnologyCollaborator
- University of BergenReponsible party - principal investigator
- International Center for Diarrheal Disease ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.